The Public Comment Period for Draft CMS FHIR® Digital Quality Measures (dQMs) is now open. Comment on Eligible Clinician dQMs, Hospital - Inpatient dQMs, and Hospital - Outpatient dQMs until February 23, 2026.
Top
Official websites use
.gov
A .gov website belongs to an official government organization in the United States.
Secure
.gov
websites use HTTPS
A
lock
(
)
or
https://
means you’ve safely connected to the
.gov
website. Share sensitive information only on official, secure websites.
["Allergy, Intolerance": "Thrombolytic medications"]
Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for thrombolytic medications used for treatment of ST-segment elevation myocardial infaction (STEMI).
Data Element Scope: This value set may use a model element related to Medication.
Inclusion Criteria: Includes RXNORM codes that represent ingredients in thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions
Data Element Scope: This value set may use a model element related to Medication.
Inclusion Criteria: Includes RXNORM codes that represent ingredients in thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions
Constrained to codes in the Allergy, Intolerance: Thrombolytic medications value set (2.16.840.1.113762.1.4.1170.4)
QDM Datatype and Definition
"Allergy Intolerance"
Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.
Timing:
- The prevalencePeriod references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
- The author dateTime references the recorded time.
eCQMs using this data element:
QDM Attributes
prevalencePeriod
prevalencePeriod is the time from onset dateTime to abatement dateTime.
type
The characterization of the reaction (e.g., hypersensitivity, rash, gastroenteric symptoms, etc.).